- Home
- INKT vs CALC Comparison
INKT vs CALC Comparison
Compare INKT & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- CALC
- Stock Information
- Founded
- INKT 2017
- CALC 2011
- Country
- INKT United States
- CALC United States
- Employees
- INKT N/A
- CALC N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- CALC Health Care
- Exchange
- INKT Nasdaq
- CALC Nasdaq
- Market Cap
- INKT 28.9M
- CALC 22.9M
- IPO Year
- INKT 2021
- CALC N/A
- Fundamental
- Price
- INKT $7.04
- CALC $1.61
- Analyst Decision
- INKT Strong Buy
- CALC Strong Buy
- Analyst Count
- INKT 2
- CALC 3
- Target Price
- INKT $37.50
- CALC $16.33
- AVG Volume (30 Days)
- INKT 14.7K
- CALC 30.2K
- Earning Date
- INKT 08-12-2025
- CALC 08-11-2025
- Dividend Yield
- INKT N/A
- CALC N/A
- EPS Growth
- INKT N/A
- CALC N/A
- EPS
- INKT N/A
- CALC N/A
- Revenue
- INKT N/A
- CALC N/A
- Revenue This Year
- INKT N/A
- CALC N/A
- Revenue Next Year
- INKT N/A
- CALC N/A
- P/E Ratio
- INKT N/A
- CALC N/A
- Revenue Growth
- INKT N/A
- CALC N/A
- 52 Week Low
- INKT $4.56
- CALC $1.42
- 52 Week High
- INKT $13.79
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- INKT 47.56
- CALC 47.03
- Support Level
- INKT $6.91
- CALC $1.42
- Resistance Level
- INKT $7.51
- CALC $1.85
- Average True Range (ATR)
- INKT 0.32
- CALC 0.15
- MACD
- INKT -0.02
- CALC -0.00
- Stochastic Oscillator
- INKT 27.28
- CALC 44.19
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.